BR112023015272A2 - Formulações farmacêuticas de centanafadina e métodos de fabricação e uso das mesmas - Google Patents
Formulações farmacêuticas de centanafadina e métodos de fabricação e uso das mesmasInfo
- Publication number
- BR112023015272A2 BR112023015272A2 BR112023015272A BR112023015272A BR112023015272A2 BR 112023015272 A2 BR112023015272 A2 BR 112023015272A2 BR 112023015272 A BR112023015272 A BR 112023015272A BR 112023015272 A BR112023015272 A BR 112023015272A BR 112023015272 A2 BR112023015272 A2 BR 112023015272A2
- Authority
- BR
- Brazil
- Prior art keywords
- centanafadine
- pharmaceutical formulations
- methods
- manufacture
- ctn
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/167—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1611—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
- A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5084—Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/26—Psychostimulants, e.g. nicotine, cocaine
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- General Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Inorganic Chemistry (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Saccharide Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163152826P | 2021-02-23 | 2021-02-23 | |
| US202163241839P | 2021-09-08 | 2021-09-08 | |
| PCT/JP2022/007314 WO2022181625A1 (en) | 2021-02-23 | 2022-02-22 | Centanafadine pharmaceutical formulations, and methods of making and using same |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112023015272A2 true BR112023015272A2 (pt) | 2023-11-07 |
Family
ID=80735736
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112023015272A BR112023015272A2 (pt) | 2021-02-23 | 2022-02-22 | Formulações farmacêuticas de centanafadina e métodos de fabricação e uso das mesmas |
Country Status (11)
| Country | Link |
|---|---|
| US (6) | US11564885B2 (https=) |
| EP (1) | EP4297734A1 (https=) |
| JP (2) | JP7787190B2 (https=) |
| KR (1) | KR20230152046A (https=) |
| AU (1) | AU2022227367A1 (https=) |
| BR (1) | BR112023015272A2 (https=) |
| CA (1) | CA3205786A1 (https=) |
| IL (1) | IL303767A (https=) |
| MX (1) | MX2023009833A (https=) |
| TW (1) | TW202302086A (https=) |
| WO (1) | WO2022181625A1 (https=) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR112023015272A2 (pt) * | 2021-02-23 | 2023-11-07 | Otsuka Pharma Co Ltd | Formulações farmacêuticas de centanafadina e métodos de fabricação e uso das mesmas |
| KR20250053128A (ko) * | 2022-08-24 | 2025-04-21 | 오츠카 세이야쿠 가부시키가이샤 | 센타나파딘을 포함하는 제약 조성물 |
| US20250375418A1 (en) * | 2022-09-02 | 2025-12-11 | Otsuka Pharmaceutical Co., Ltd. | 1-(naphthalen-2-yl)-3-azabicyclo[3.1.0]hexane for treating major depressive disorder |
| WO2025183181A1 (en) | 2024-02-28 | 2025-09-04 | Otsuka Pharmaceutical Co., Ltd. | Use of centanafadine in treatment of adhd symptoms |
| US12502358B1 (en) | 2024-08-13 | 2025-12-23 | Innovate Therapeutics Llc | Centanafadine multiphasic controlled-release pharmaceutical formulation |
| US12303604B1 (en) | 2024-10-16 | 2025-05-20 | Currax Pharmaceuticals Llc | Pharmaceutical formulations comprising naltrexone and/or bupropion |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2809918A (en) | 1955-10-17 | 1957-10-15 | Victor M Hermelin | Sustained release pharmaceutical preparations |
| DE2010416B2 (de) | 1970-03-05 | 1979-03-29 | Hoechst Ag, 6000 Frankfurt | Oral anwendbare Arzneiform mit Retardwirkung |
| FR2471186A1 (fr) | 1979-12-10 | 1981-06-19 | Roussel Uclaf | Nouveaux comprimes a delitescence colique, ainsi que leur procede de preparation |
| US4728512A (en) | 1985-05-06 | 1988-03-01 | American Home Products Corporation | Formulations providing three distinct releases |
| US4794001A (en) | 1986-03-04 | 1988-12-27 | American Home Products Corporation | Formulations providing three distinct releases |
| US5225202A (en) | 1991-09-30 | 1993-07-06 | E. R. Squibb & Sons, Inc. | Enteric coated pharmaceutical compositions |
| GB9416600D0 (en) * | 1994-08-17 | 1994-10-12 | Smithkline Beecham Plc | Pharmaceutical formulation |
| US6132724A (en) | 1998-04-29 | 2000-10-17 | City Of Hope National Medical Center | Allelic polygene diagnosis of reward deficiency syndrome and treatment |
| US8747895B2 (en) * | 2004-09-13 | 2014-06-10 | Aptalis Pharmatech, Inc. | Orally disintegrating tablets of atomoxetine |
| WO2006133349A2 (en) | 2005-06-08 | 2006-12-14 | Alpharma, Inc. | Orally disintegrable sleep aid formulations |
| EP1915146A4 (en) * | 2005-07-27 | 2010-06-02 | Dov Pharmaceutical Inc | NOVEL 1-ARYL-3-AZABICYCLO [3.1.0] HEXANEES. PREPARATION AND USE FOR THE TREATMENT OF NEUROPSYCHIATRIC DISEASES |
| ES2529455T3 (es) * | 2006-05-12 | 2015-02-20 | Shire Llc | Sistema de administración de fármacos por dosis controladas |
| US8846100B2 (en) * | 2006-05-12 | 2014-09-30 | Shire Llc | Controlled dose drug delivery system |
| US20140206740A1 (en) * | 2011-07-30 | 2014-07-24 | Neurovance, Inc. | Use Of (1R,5S)-(+)-(Napthalen-2-yl)-3-Azabicyclo[3.1.0]Hexane In The Treatment Of Conditions Affected By Monoamine Neurotransmitters |
| CN107335057A (zh) | 2012-07-27 | 2017-11-10 | 韦尔斯利医药有限公司 | 用于缓解尿频的药物制剂及其使用方法 |
| CN106029637A (zh) | 2013-12-09 | 2016-10-12 | 纽罗万斯公司 | 新的组合物 |
| EP3069715A1 (en) * | 2015-03-20 | 2016-09-21 | Salmon Pharma GmbH | Immediate release dosage forms of Atomoxetine |
| US20180008575A1 (en) | 2016-07-11 | 2018-01-11 | Neurovance, Inc. | Methods of treating binge eating disorder |
| BR112023015272A2 (pt) * | 2021-02-23 | 2023-11-07 | Otsuka Pharma Co Ltd | Formulações farmacêuticas de centanafadina e métodos de fabricação e uso das mesmas |
-
2022
- 2022-02-22 BR BR112023015272A patent/BR112023015272A2/pt unknown
- 2022-02-22 US US17/677,726 patent/US11564885B2/en active Active
- 2022-02-22 CA CA3205786A patent/CA3205786A1/en active Pending
- 2022-02-22 EP EP22709827.4A patent/EP4297734A1/en active Pending
- 2022-02-22 WO PCT/JP2022/007314 patent/WO2022181625A1/en not_active Ceased
- 2022-02-22 IL IL303767A patent/IL303767A/en unknown
- 2022-02-22 KR KR1020237030686A patent/KR20230152046A/ko active Pending
- 2022-02-22 MX MX2023009833A patent/MX2023009833A/es unknown
- 2022-02-22 AU AU2022227367A patent/AU2022227367A1/en active Pending
- 2022-02-22 TW TW111106378A patent/TW202302086A/zh unknown
- 2022-02-22 JP JP2023547454A patent/JP7787190B2/ja active Active
- 2022-11-30 US US18/072,473 patent/US11759426B2/en active Active
-
2023
- 2023-06-01 US US18/204,728 patent/US11980690B2/en active Active
-
2024
- 2024-01-30 US US18/427,459 patent/US12156941B2/en active Active
- 2024-10-22 US US18/923,418 patent/US12370144B2/en active Active
-
2025
- 2025-06-25 US US19/249,883 patent/US20250319030A1/en active Pending
- 2025-08-13 JP JP2025134582A patent/JP2025183214A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| AU2022227367A1 (en) | 2023-08-03 |
| US20250041225A1 (en) | 2025-02-06 |
| US11564885B2 (en) | 2023-01-31 |
| US20230338293A1 (en) | 2023-10-26 |
| JP7787190B2 (ja) | 2025-12-16 |
| MX2023009833A (es) | 2023-09-04 |
| TW202302086A (zh) | 2023-01-16 |
| US20240165030A1 (en) | 2024-05-23 |
| JP2024506595A (ja) | 2024-02-14 |
| EP4297734A1 (en) | 2024-01-03 |
| US11980690B2 (en) | 2024-05-14 |
| US12156941B2 (en) | 2024-12-03 |
| AU2022227367A9 (en) | 2024-10-17 |
| US11759426B2 (en) | 2023-09-19 |
| IL303767A (en) | 2023-08-01 |
| JP2025183214A (ja) | 2025-12-16 |
| US20250319030A1 (en) | 2025-10-16 |
| US20220265557A1 (en) | 2022-08-25 |
| CA3205786A1 (en) | 2022-09-01 |
| WO2022181625A1 (en) | 2022-09-01 |
| US12370144B2 (en) | 2025-07-29 |
| US20230104529A1 (en) | 2023-04-06 |
| KR20230152046A (ko) | 2023-11-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112023015272A2 (pt) | Formulações farmacêuticas de centanafadina e métodos de fabricação e uso das mesmas | |
| BR112022003514A2 (pt) | Degradadores bifuncionais de brd9 e seus métodos de uso | |
| BR112021021284A2 (pt) | Composto, composição farmacêutica, e, métodos para o tratamento ou profilaxia de doenças inflamatórias da pele, doenças respiratórias, doenças gastrointestinais, doenças oculares, cânceres, doenças reumáticas, doenças desmielinizantes e doenças fibróticas e de inibição da atividade de proteínas de bromodomínio e domínio terminal extra | |
| EA202090573A1 (ru) | Составы нирапариба | |
| CA3030422C (en) | Stabilizing excipients for therapeutic protein formulations | |
| AU2018231044A8 (en) | Pharmaceutical formulations of phloroglucinol and trimethylphloroglucinol | |
| JOP20190193A1 (ar) | ممركبات 2-أريل غير متجانس-3-أكسو-2، 3-ثنائي هيدرو بيريدازين-4-كربوكساميد لمعالجة السرطان | |
| BR112022009209A2 (pt) | Derivado de amida e método de preparação e uso do mesmo na medicina | |
| CU20210077A7 (es) | Extractos bacterianos estables como fármacos | |
| BR112021011325A2 (pt) | Derivados de rapamicina | |
| MX2021010041A (es) | Composiciones farmaceuticas que comprenden inhibidores de la proteina quinasa akt. | |
| BR112021018707A2 (pt) | Formulações compreendendo melflufeno | |
| JOP20220281A1 (ar) | مركبات وتركيبات لتثبيط نشاط hif2 ألفا وطرق لاستخدامها | |
| CY1121921T1 (el) | Φαρμακευτικα σκευασματα | |
| EA202190308A1 (ru) | Применение пролекарств рилузола для лечения болезни альцгеймера | |
| BR112022019864A2 (pt) | Composto de oxofenilarsina deuterada e uso do mesmo | |
| BR112023025552A2 (pt) | Composições estabilizadas de apilimod e usos das mesmas | |
| EP4171544A4 (en) | PHARMACEUTICAL FORMULATIONS OF GRISEOFULVINE FOR LONG-TERM EYE ADMINISTRATION | |
| CL2019003467A1 (es) | Compuestos bicíclicos 5,6-fusionados y composiciones para el tratamiento de enfermedades parasitarias. | |
| MX2023013970A (es) | Uso de 5-nitro-8-hidroxiquinolina. | |
| MX2024011654A (es) | Formulaciones que comprenden melfalan flufenamida y ciclodextrina | |
| BR112022010126A2 (pt) | Compostos de heteroarila e usos terapêuticos dos mesmos em condições associadas à alteração da atividade da betaglucocerebrosidase | |
| CL2019002899A1 (es) | Formulaciones con mayor estabilidad y biodisponibilidad para administración de (e)-2,6-dialcoxiestiril bencilsulfonas sustituidas en 4. | |
| UY37413A (es) | Formulaciones de liberación inmediata de oprozomib | |
| BR112022026126A2 (pt) | Formulações |